Chemomab Therapeutics Announces Third Quarter 2024 Financial …

2 days ago · TEL AVIV, Israel, November 14, 2024 --Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative …

CouponFollow Extension

$2
OFF

CMMB - Chemomab Therapeutics Announces Third Quarter 2024...

1 week from now

2 days ago · Research and Development (R&D) Expenses : R&D expenses were $2.8 million for the third quarter of 2024, compared to $3.4 million for the third quarter of 2023. The decrease …

marketwirenews.com

$12
OFF

Chemomab Therapeutics Announces Second Quarter 2024 …

1 week from now

Aug 21, 2024 · Cash Position: Cash, cash equivalents and short-term bank deposits were $12.8 million as of June 30, 2024, compared to $19.9 million as of December 31, 2023. On July 30, …

chemomab.com

$0.35
OFF

BrainStorm Cell Therapeutics Announces Third Quarter 2024 …

1 week from now

2 days ago · Financial Results for the Third Quarter Ended September 30, 2024 Cash, cash equivalents, and restricted cash amounted to approximately $0.35 million , as of September …

morningstar.com

$2
OFF

Chemomab Therapeutics Announces Third Quarter 2024 …

1 week from now

2 days ago · Research and Development (R&D) Expenses: R&D expenses were $2.8 million for the third quarter of 2024, compared to $3.4 million for the third quarter of 2023. The decrease …

chemomab.com

$0
OFF

Chemomab Therapeutics Announces First Quarter 2024 Financial …

1 week from now

May 9, 2024 · General and Administrative (G&A) Expenses: G&A expenses were $0.9 million for the first quarter of 2024, compared to $2.2 million for the first quarter of 2023. The decrease in …

chemomab.com

$3
OFF

Chemomab Therapeutics Announces Third Quarter 2024 Financial …

1 week from now

2 days ago · Net Loss: Net loss was $3.5 million, or a net loss of approximately $0.01 per basic and diluted ordinary share for the third quarter of 2024, compared to $4.1 million, or a net loss …

tmcnet.com

$5
OFF

Inhibikase Therapeutics Reports Third Quarter Financial ... - BioSpace

1 week from now

1 day ago · Third Quarter Financial Results. Net Loss: Net loss for the quarter ended September 30, 2024, was $5.8 million, or $0.65 per share, compared to a net loss of $4.6 million, or $0.75 …

biospace.com

$3
OFF

Chemomab Therapeutics Announces Third Quarter 2024

1 week from now

2 days ago · Net Loss: Net loss was $3.5 million, or a net loss of approximately $0.01 per basic and diluted ordinary share for the third quarter of 2024, compared to $4.1 million, or a net loss …

globenewswire.com

FAQs about Chemomab Therapeutics Announces Third Quarter 2024 Financial … Coupon?

How do I contact chemomab after a press release is issued?

Investors who would like to discuss the financial results or business update after the press release has been issued are invited to contact the company at [email protected]. Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. ...

Who is chemomab Therapeutics?

Chemomab Therapeutics is a clinical-stage biotech company discovering and developing innovative therapeutics for conditions that involve inflammation and fibrosis and have high unmet need. Fibrosis-related diseases are a significant unmet need that dramatically affect patients' health and quality of life. ...

When will chemomab's CM-101 PSC Phase 2 Spring trial results be presented?

On October 15, 2024, Chemomab announced that on November 18, 2024, PSC expert Dr. Christopher Bowlus will be presenting a late-breaking oral presentation discussing the CM-101 PSC Phase 2 SPRING trial results at the AASLD The Liver Meeting ® 2024. ...

What happened to chemomab?

On July 30, 2024, Chemomab announced the closing of a private placement that resulted in gross proceeds of approximately $10 million to the company. Existing investors such as OrbiMed and new investors including HBM Partners and Sphera Biotech Master Fund participated in the financing. ...

Can chemomab be used in clinical trials?

Chemomab has reported positive results from four clinical trials of CM-101 in patients. ...

Is chemomab safe for patients with PSC?

On July 25, 2024, Chemomab reported topline results from the CM-101 Phase 2 SPRING trial in patients with PSC. CM-101 met the primary study endpoint, demonstrating a favorable safety profile over the 15-week treatment period. ...